DERM - Dermira, Inc.
| Previous Close | 8.23 |
| Open | 8.32 |
| Bid | 8.24 x 800 |
| Ask | 8.26 x 1200 |
| Day's Range | 8.12 - 8.39 |
| 52 Week Range | 6.00 - 15.48 |
| Volume | 207,943 |
| Avg. Volume | 676,088 |
| Market Cap | 448.783M |
| Beta (3Y Monthly) | 1.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.86 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.71 |
- Thomson Reuters StreetEvents
Edited Transcript of DERM earnings conference call or presentation 7-Aug-19 8:30pm GMT
Q2 2019 Dermira Inc Earnings Call
- Zacks
Dermira (DERM) Reports Q2 Loss, Tops Revenue Estimates
Dermira (DERM) delivered earnings and revenue surprises of 63.33% and 95.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- QBREXZA™ cloth net product sales of $8.1M, more than triple first quarter 2019 sales
- Business Wire
Dermira to Report Second Quarter 2019 Results and Host Conference Call on Wednesday, August 7, 2019
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, will report financial results for the quarter ended June 30, 2019 and provide an operational update after market close on Wednesday, August 7, 2019. Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products.
- Zacks
Earnings Preview: Dermira (DERM) Q2 Earnings Expected to Decline
Dermira (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Kiplinger
5 Biotech Stocks to Buy for Blockbuster Potential
Biotechnology has boomed over the past few decades as our understanding of living organisms and the human machine has swelled. As a result, biotech stocks have become some of the most exciting growth plays on Wall Street.And their potential to deliver sky-high returns is especially explosive when they're developing a drug with blockbuster potential.Blockbuster drugs are those popular treatments that generate annual sales of at least $1 billion. They're uncommon: A drug must have the right combination of price and number of potential patients, so only a handful of treatments at any given time even have the potential to become billion-dollar products. And not all of them live up to their potential.So how can you pinpoint biotech stocks with these kind of superstar drugs in the pipeline? We suggest turning to Wall Street's pros.Here are five promising biotech stocks to buy for their blockbuster-drug potential. TipRanks data shows that all five stocks boast a "Strong Buy" consensus among the Wall Street analysts covering them, based on ratings given during the past three months. SEE ALSO: The 20 Best Small-Cap Dividend Stocks to Buy
- Simply Wall St.
Should You Be Pleased About The CEO Pay At Dermira, Inc.'s (NASDAQ:DERM)
Tom Wiggans has been the CEO of Dermira, Inc. (NASDAQ:DERM) since 2010. First, this article will compare CEO...
- Business Wire
Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis
Almirall, S.A. (BME:ALM) and Dermira, Inc. (DERM) announced today that Almirall has exercised its option to license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe. Almirall and Dermira previously entered into an option and license agreement in February 2019 pursuant to which Almirall was granted this exclusive option in exchange for an upfront option fee of $30 million.
- Business Wire
Dermira to Present at the Raymond James Life Sciences and MedTech Conference
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present at the Raymond James Life Sciences and MedTech Conference in New York on June 18, 2019 at 2:25 p.m. ET. Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products.
- Markit
See what the IHS Markit Score report has to say about Dermira Inc.
Dermira Inc NASDAQ/NGS:DERMView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding DERM is favorable, with net inflows of $2.36 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- TheStreet.com
Dermira Advances on Analyst Upgrade to Buy
climbed 3.4% to $9.29 Thursday after Mizuho upgraded shares of the biopharmaceutical company to buy from neutral. Analyst Irina Koffler also lowered her price target for the Menlo Park, California-based company to $14 from $17 a share.
- Thomson Reuters StreetEvents
Edited Transcript of DERM earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Dermira Inc Earnings Call
Motley FoolDermira (DERM) Q1 2019 Earnings Call Transcript
DERM earnings call for the period ending March 31, 2019.
- Simply Wall St.
Did You Manage To Avoid Dermira's (NASDAQ:DERM) Painful 63% Share Price Drop?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is doubtless a positive to see that the Dermira, Inc. (NASDAQ:DERM) share price has gained some...
- Zacks
Dermira (DERM) Reports Q1 Loss, Lags Revenue Estimates
Dermira (DERM) delivered earnings and revenue surprises of -13.74% and -6.77%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Dermira: 1Q Earnings Snapshot
The Menlo Park, California-based company said it had a loss of $1.49 per share. The skin condition drug developer posted revenue of $2.5 million in the period, falling short of Street forecasts. Three ...
- Business Wire
Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update
Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update
- Business Wire
Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, will report financial results for the quarter ended March 31, 2019 and provide an operational update after market close on Tuesday, May 7, 2019. Dermira also has early-stage research and development programs in other areas of dermatology.
- Zacks
Dermira (DERM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Dermira (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
Here's Why Dermira Shot Up 62% in March
Results from a mid-stage study with a potential new eczema drug gave investors a reason to cheer.
- Business Wire
Dermira to Present at the 18th Annual Needham Healthcare Conference
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in a fireside chat at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 12:50 p.m. ET. Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products.
- Simply Wall St.
Does The Dermira, Inc. (NASDAQ:DERM) Share Price Fall With The Market?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you're interested in Dermira, Inc. (NASDAQ:DERM), then you might want to consider its beta (a measure of share price volat...
